Haruna Shinohara-Tomizawa
Chugai Life Science Park Yokohama, 216, Totsuka Cho, Totsuka Ku
Yokohama, 2448602, Japan
Yokohama, 2448602, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Anti-IL-6R antibody treatment changes microglial phenotype in AQP4 peptide-immunized mice, leading to suppression of myelitis severity.
Journal: Journal of neuroimmunology
Published: January 15, 2025
Anti-IL-6 receptor antibody suppresses onset of paralytic symptoms in AQP4 peptide-immunized mice without lowering bone strength or mineral density.
Journal: Journal of neuroimmunology
Published: December 03, 2024
IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model.
Journal: Frontiers in neurology
Published: December 15, 2023
Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice.
Journal: Journal of neuroimmunology
Published: February 03, 2023
Interleukin-6: evolving role in the management of neuropathic pain in neuroimmunological disorders.
Journal: Inflammation and regeneration
Published: May 31, 2021
New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: January 28, 2021
Anti-IL-6 Receptor Antibody Inhibits Spontaneous Pain at the Pre-onset of Experimental Autoimmune Encephalomyelitis in Mice.
Journal: Frontiers in neurology
Published: December 28, 2018
Spontaneous recovery of fear differs among early - late adolescent and adult male mice.
Journal: The International journal of neuroscience
Published: July 17, 2018
Anti-IL-6 receptor antibody improves pain symptoms in mice with experimental autoimmune encephalomyelitis.
Journal: Journal of neuroimmunology
Published: December 27, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026